The bill seeks to repeal section 338.010 of the Revised Statutes of Missouri and replace it with five new sections aimed at improving access to medical products, particularly insulin and diabetes-related devices. Key provisions include allowing pharmacists to dispense an emergency supply of insulin without a current prescription under certain conditions, and requiring pharmacy benefits managers to reimburse pharmacies at least the actual acquisition cost of dispensed drugs, along with a minimum dispensing fee of $15 per prescription. Additionally, the bill sets limits on out-of-pocket costs for patients, capping the cost of a thirty-day supply of covered prescription insulin drugs at $35 and limiting the cost of diabetes and epinephrine delivery devices to $100 each, with annual adjustments based on the Consumer Price Index. Furthermore, the bill introduces a new section, 376.689, which mandates the Department of Commerce and Insurance, in collaboration with other departments, to produce a public report by November 1, 2026. This report will summarize pricing practices for insulin and related devices, as well as factors influencing health coverage plan pricing, and will include public policy recommendations to control and prevent overpricing. The provisions for this report will expire on January 1, 2027, highlighting the urgency of addressing healthcare pricing issues in Missouri.

Statutes affected:
Introduced (4560H.01): 338.010, 338.740, 376.681, 376.687, 376.689